SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Eris Lifesciences - Quaterly Results

05 Aug 2022 Evaluate
The Revenue for the quarter ended  June 2022 of Rs. 3287.60 millions grew by 7.33 % from Rs. 3062.96 millions.The Company's Net profit for the June 2022 quarter have declined marginally to Rs. 955.91  millions as against Rs. 1067.20 millions reported during the corresponding quarter ended.Operating Profit saw a handsome growth to 1295.59 millions from 1289.91 millions in the quarter ended June 2022.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 3287.60 3062.96 7.33 3287.60 3062.96 7.33 12157.30 11088.34 9.64
Other Income 33.72 64.47 -47.70 33.72 64.47 -47.70 289.89 99.98 189.95
PBIDT 1295.59 1289.91 0.44 1295.59 1289.91 0.44 5129.84 4273.12 20.05
Interest 72.26 4.63 1460.69 72.26 4.63 1460.69 29.91 7.78 284.45
PBDT 1223.33 1285.28 -4.82 1223.33 1285.28 -4.82 5099.93 4265.34 19.57
Depreciation 149.72 112.29 33.33 149.72 112.29 33.33 514.55 376.40 36.70
PBT 1073.61 1172.99 -8.47 1073.61 1172.99 -8.47 4585.38 3888.94 17.91
TAX 117.70 105.79 11.26 117.70 105.79 11.26 413.46 382.89 7.98
Deferred Tax -76.24 -102.42 -25.56 -76.24 -102.42 -25.56 -388.26 -318.95 21.73
PAT 955.91 1067.20 -10.43 955.91 1067.20 -10.43 4171.92 3506.05 18.99
Equity 135.97 135.78 0.14 135.97 135.78 0.14 135.93 135.78 0.11
PBIDTM(%) 39.41 42.11 -6.42 39.41 42.11 -6.42 42.20 38.54 9.49

Eris Lifesciences Share Price

1446.50 -18.90 (-1.29%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×